Chronic lymphocytic leukaemia: Correction
Chronic lymphocytic leukaemia: Correction
Nature Reviews Disease Primers 3, 16096 (2017)
In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients. ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil146.
Kipps, Thomas J.
0fd44186-1f31-4fc9-aa1e-c7bcf9094258
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Wu, Catherine J.
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Croce, Carlo M.
309d71ed-c41e-420a-b0bf-d53d5a8caa91
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Wierda, William G.
a3df6934-fb1c-4b26-86fd-34728b0e4cdc
O'brien, Susan
6dde4fb1-1fe4-4593-b82a-3d46177816ad
Gribben, John
d442ac5b-2cc3-469c-9222-a92a46584a8d
Rai, Kanti
e9798f67-6b49-4292-884f-f8123e8c2647
9 February 2017
Kipps, Thomas J.
0fd44186-1f31-4fc9-aa1e-c7bcf9094258
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Wu, Catherine J.
ccfe9fd3-5487-4b67-a02c-6e34ae3d39a4
Croce, Carlo M.
309d71ed-c41e-420a-b0bf-d53d5a8caa91
Packham, Graham
fdabe56f-2c58-469c-aadf-38878f233394
Wierda, William G.
a3df6934-fb1c-4b26-86fd-34728b0e4cdc
O'brien, Susan
6dde4fb1-1fe4-4593-b82a-3d46177816ad
Gribben, John
d442ac5b-2cc3-469c-9222-a92a46584a8d
Rai, Kanti
e9798f67-6b49-4292-884f-f8123e8c2647
Kipps, Thomas J., Stevenson, Freda K., Wu, Catherine J., Croce, Carlo M., Packham, Graham, Wierda, William G., O'brien, Susan, Gribben, John and Rai, Kanti
(2017)
Chronic lymphocytic leukaemia: Correction.
Nature Reviews Disease Primers, 3, [17008].
(doi:10.1038/nrdp.2017.8).
Abstract
Nature Reviews Disease Primers 3, 16096 (2017)
In the version of the article originally published, a typographical error has now been corrected. The statement now reads: Approval of ibrutinib as initial therapy was based on the results of a randomized trial that showed a significant improvement in median PFS and overall survival in patients. ≥65 years of age without del(17p) who were treated indefinitely with ibrutinib than in patients treated for up to 48 weeks with chlorambucil146.
This record has no associated files available for download.
More information
Accepted/In Press date: 31 January 2017
e-pub ahead of print date: 9 February 2017
Published date: 9 February 2017
Identifiers
Local EPrints ID: 421828
URI: http://eprints.soton.ac.uk/id/eprint/421828
PURE UUID: 4172a548-2b34-47e6-9e85-d3f3e8cabdfa
Catalogue record
Date deposited: 29 Jun 2018 16:30
Last modified: 16 Mar 2024 03:14
Export record
Altmetrics
Contributors
Author:
Thomas J. Kipps
Author:
Catherine J. Wu
Author:
Carlo M. Croce
Author:
William G. Wierda
Author:
Susan O'brien
Author:
John Gribben
Author:
Kanti Rai
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
